Myelodysplastic Syndrome

Bone marrow inflammation predicts leukemia risk

Cancer is generally thought to arise from genetic damage within individual cells, but recent evidence has suggested that abnormal signaling in the surrounding tissue also plays an important role. In a study published September ...

Oct 03, 2016
popularity37 comments 0

The myelodysplastic syndromes (MDS, formerly known as preleukemia) are a diverse collection of hematological (blood-related) medical conditions that involve ineffective production (or dysplasia) of the myeloid class of blood cells.

Patients with MDS often develop severe anemia and require frequent blood transfusions. In most cases, the disease worsens and the patient develops cytopenias (low blood counts) due to progressive bone marrow failure. In about one third of patients with MDS, the disease transforms into acute myelogenous leukemia (AML), usually within months to a few years.

The myelodysplastic syndromes are all disorders of the stem cell in the bone marrow. In MDS, hematopoiesis (blood production) is disorderly and ineffective. The number and quality of blood-forming cells decline irreversibly, further impairing blood production.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

New trials offer hope for TB treatment

Researchers at the University of St Andrews are one step closer to finding a shorter, more effective treatment for TB, according to a new paper published by The Lancet Infectious Diseases.